Eton Pharmaceuticals Inc

ETONNASDAQ · USD
63.65USD0.00 (-0.36%)
6610

Eton Pharmaceuticals Inc (ETON) Option Chain

Eton Pharmaceuticals Inc trades at $63.65, down 0.36%, with an IV Rank of 11.51%. This is low versus the past year, and the company carries a market cap of $1,836M in the Drug Manufacturers - Specialty & Generic industry. On the Nov 20, 2026 chain, the at the money $65.00 strike shows calls at $0.20 / $4.10 and puts at $0.90 / $4.50, both carrying about $1.75 of extrinsic value and a roughly 50% probability of expiring out of the money. Volume is heaviest on the $60.00 calls, at 16 contracts, and the $50.00 puts, at 3, as of Nov 17, 2026.

Read more

Tracking the ETON option chain helps you see every strike and expiry on Eton Pharmaceuticals Inc in one view, so you can quickly identify contracts that fit your thesis and your risk. It lays out bids, asks, volume, open interest, and Greeks across calls and puts, giving you the full map of ETON options activity at a glance. Use our scanner to monitor the ETON option chain in real time and filter for the trades that actually meet your criteria.

An option chain is the complete listing of all available option contracts on an underlying, organized by expiration date and strike price. For ETON stock options, the chain shows call and put data side by side, making it easy to compare premiums, assess liquidity, and spot pricing dislocations. Reading it well means looking beyond the last price. Implied volatility by strike, volume to open interest ratios, and bid ask spreads all show where ETON options are being actively traded, and where they are not.

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; and Rezipres, a ready-to-use formulation of a molecule that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia.

2026-11-20
5 strikes
Default
CALLsPUTs
Prob. OTM %Open InterestVolumeExtrinsic ValueIntrinsic ValueBidAskStrikeMoneyness %BidAskIntrinsic ValueExtrinsic ValueVolumeOpen InterestProb. OTM %
3.8788000.958.658.1011.1055.00-13.97—2.150.002.1501896.13
23.39337160.883.652.956.1060.00-6.15—2.650.002.6501676.61
59.1453132.150.000.204.1065.00+1.670.904.501.351.350740.86
86.818320.580.000.051.1070.00+9.494.907.706.35-0.050013.19
97.392302.250.00—2.2575.00+17.329.6013.1011.35-0.00002.61

As of Nov 17, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →

Stock Statistics

  • IndustryDrug Manufacturers - Specialty & Generic
  • SectorHealthcare
  • IV Rank11.51% Low
  • Market cap (M$)1,836
  • 52 weeks high-9.90%
  • 52 weeks low346.04%
  • Analyst recommendationStrong Buy
    1.00
  • Target price$80.75
    26.87% above the current stock price
  • Dividend—
  • Payout ratio—
  • Earnings date2026-11-05
  • P/E42.17
  • Future P/E21.99
  • EPS (ttm)1.51
  • EPS growth next 5 years125.39%

As of Nov 17, 2026